Sugi Predict

Sugi Predict / Compounds / SCHEMBL25225534

SCHEMBL25225534

SCHEMBL25225534

O=[N+]([O-])c1ccc(N2CCC(O)(CCO)CC2)cn1

nearest known ligand 0.59

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.59
▸ POLB P06746 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.47
▸ RAB9A P51151 1/20 0.47
▸ CHRNB2 P17787 3/20 0.46
▸ CHRNA4 P43681 3/20 0.46
▸ CHRNB4 P30926 2/20 0.46
▸ CHRNA3 P32297 2/20 0.46
▸ TGM2 P21980 4/20 0.36
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.33
▸ MLYCD O95822 1/20 0.33
▸ CRBN Q96SW2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30422139 1.00 MAPT (0.59) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL21245532 0.90 MAPT (0.62) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL31303379 0.90 MAPT (0.62) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL23104467 0.83 MAPT (0.59) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL23104357 0.83 MAPT (0.64) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL23104352 0.83 MAPT (0.56) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL612209 0.82 MAPT (0.65) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL23104443 0.81 MAPT (0.60) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL23114481 0.80 MAPT (0.53) MAPTPOLBSMN1; SMN2RAB9ACHRNB2
SCHEMBL23133383 0.80 MAPT (0.53) MAPTPOLBSMN1; SMN2RAB9ACHRNB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240383877-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF UBIX THERAPEUTICS, INC. (KR) 2024-11-21 — — US disclosed
US-12122763-B2 Substituted piperidines for androgen receptor degradation UBIX THERAPEUTICS, INC. (KR) 2024-10-22 — — US disclosed
US-20230348427-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF UBIX THERAPEUTICS, INC. (KR) 2023-11-02 — — US disclosed
US-20230348427-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF UBIX THERAPEUTICS, INC. (KR) 2023-11-02 — — US disclosed
EP-4186904-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF Ubix Therapeutics, Inc. (KR) 2023-05-31 — — EP disclosed
WO-2022019597-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF 주식회사 유빅스테라퓨틱스 2022-01-27 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348427-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF AR, NR5A1, SHBG MAPT 2978/4885POLB 2788/4885SMN1; SMN2 3395/4885
US-20240383877-A1 COMPOUND FOR ANDROGEN RECEPTOR DEGRADATION, AND PHARMACEUTICAL USE THEREOF AR, NR5A1, ESRRA MAPT 4124/4885POLB 2117/4885SMN1; SMN2 3088/4885
US-12122763-B2 Substituted piperidines for androgen receptor degradation AR, NR5A1, ESRRA MAPT 4610/4885POLB 2099/4885SMN1; SMN2 3075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.